Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

Oncogene volume 21, pages 7593–7597 (2002)Cite this article

Abstract

Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. We studied the biological characteristics of these tumours by comparing the overexpression of oncogenes ERBB2, MYC, CCND1 and RHOC and TP53 gene mutation rates in IBC with those found in locally advanced and not otherwise specified breast cancers. The prevalence of the TP53 mutation was much higher in IBC than in the two other types of cancer (57% vs 30). Unexpectedly, however, in IBC tumours, histological grade was independent of TP53 status. In addition, ERBB2 overexpression was twice as frequent in inflammatory as in non-inflammatory tumours, whereas the frequencies of MYC, CCND1 and RHOC overexpression did not vary significantly among the three types of breast cancer. These findings suggest that IBC tumours constitute a distinct subset with a specific pathogenesis. Given the importance of TP53 and ERBB2 in the response to treatments, our observations have important therapeutic implications for the clinical management of IBC patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Bertheau P, Plassa L, Espié M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de Thé H . 2002 The Lancet in press

  • Bièche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, Vidaud M . 1999a Cancer Res. 59: 2759–2765

  • Bièche I, Olivi M, Nogues C, Vidaud M, Lidereau R . 2002 Br. J. Cancer 86: 580–586

  • Bièche I, Onody P, Laurendeau I, Olovi M, Vidaud D, Lidereau R, Vidaud M . 1999b Clin. Chem. 45: 1148–1156

  • Bunz F, Hwang P, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler K, Vogelstein B . 1999 J. Clin. Invest. 104: 263–269

  • Chang S, Parker S, Pham T, Buzdar A, Hursting S . 1998 Cancer 82: 2366–2372

  • Chomczyniski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159

  • Clark EA, Golub TR, Lander ES, Hynes RO . 2000 Nature 406: 532–535

  • Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L, Wolter J, Paton V, Shak S, Lieberman G, Slamon D . 1999 J. Clin. Oncol. 17: 2639–2648

  • Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J . 1992 Cancer Res. 52: 5291–5298

  • Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C . 2000 Cancer Res. 60: 1077–1083

  • de Cremoux P, Salomon AV, Liva S, Dendale R, Bouchind'homme B, Martin E, Sastre-Garau X, Magdelenat H, Fourquet A, Soussi T . 1999 J. Natl. Cancer Inst. 91: 641–643

  • Degeorges A, de Roquancourt A, Extra J, Espié M, Bourstyn E, de Crémoux P, Soussi T, Marty M . 1998 Breast Cancer Res. Treat. 47: 47–55

  • Dillman O . 1999 Cancer Biother. Radiopharm. 14: 5–10

  • Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B . 2000 The Lancet 355: 1745–1750

  • Elston C . 1987 Diagnostic histopathology of the breast. Page D and Anderson TJ (eds) New York: Churchill Livingstone pp. 303–307

    Google Scholar 

  • Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher JM, Bron L, Benhatter J, Tada M, Van Meir EG, Estreicher A, Iggo RD . 1995 Proc. Natl. Acad. Sci. USA 92: 3963–3967

  • Garcia I, Dietrich Y, Aapro M, Vauthier L, Vadas L, Engel E . 1989 Cancer Res. 49: 6675–6679

  • Gradishar W . 1996 Semin. Surg. Oncol. 12: 352–363

  • Guerin M, Barrois M, Terrier M-J, Spielmann M, Riou G . 1988 Oncogenes Res. 3: 21–31

  • Guerin M, Gabillot M, Mathieu M, Travagli J, Spielmann M, Andrieu N, Riou G . 1989 Int. J. Cancer 43: 201–208

  • Huang G, Hobbs S, Walton M, Epstein R . 2002 Br. J. Cancer 86: 1104–1109

  • Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A . 1996 J. Pathol. 179: 31–38

  • Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D . 2000 Nature 406: 747–752

  • Révillion F, Bonneterre J, Peyrat J . 1998 Eur. J. Cancer 34: 791–808

  • Sainsbury J, Anderson T, Morgan D . 2000 Brit. Med. J. 321: 745–750

  • Saitoh S, Cunningham J, De Vries EMG, McGovern RM, Schroeder JJ, Hartman A, Blaszyk H, Wold LE, Schaid D, Sommer SS, Kovach JS . 1994 Oncogene 9: 2869–2875

  • Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J, Longy M, Jacquemier J, Sobol H, Eisinger F, Birnbaum D . 1997 Cancer Res. 57: 5469–5474

  • Sato T, Yuyama Y, Watabe K, Okazaki A, Toda K, Okazaki M, Hirata K . 1997 Cancer Lett. 115: 47–55

  • Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M . 1999 Br. J. Cancer 81: 1385–1391

  • Seshadri R, Leong A-Y, McCaul K, Firgaira F, Setlur V, Horsfall D . 1996 Int. J. Cancer 69: 135–141

  • Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, Salvadori B, Veronesi U . 1996 Clin. Cancer Res. 2: 2007–2013

  • Sjöstrom J, Krajewski S, Franssila K, Niskanen E, Wasenius V-M, Nordling S, Reed J, Blomqvist C . 1998 Br. J. Cancer 78: 812–815

  • Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen M, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese J, Brown P, Botstein D, Lonning P, Borresen-Dale A-L . 2001 Proc. Natl. Acad. Sci. USA 98: 10869–10874

  • Stebbing J, Copson E, O'Reilly S . 2000 Cancer Treat. Rev. 26: 287–290

  • Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H, Fukumoto M . 1998 Br. J. Cancer 77: 147–152

  • Turpin E, Dalle B, de Roquancourt A, Plassa L, Marty M, Janin A, Beuzard Y, de Thé H . 1999 Oncogene 18: 7834–7837

  • UICC. 1997 TNM classification of malignant tumours. Sobin L and Wittekind C (eds) New York: Wiley-Liss pp. 123–130

  • Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, Ögmundsdottir HM, Eyfjörd JE . 1997 APMIS 105: 121–130

  • van t'Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH . 2002 Nature 415: 530–536

  • van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD . 1999 Clin. Cancer Res. 5: 2511–2519

  • Vincent-Salomon A, Carton M, Freneaux P, Palangie T, Beuzeboc P, Mouret E, de Crémoux P, Coué O, Zafrani B, Nicolas A, Clough K, Fourquet A, Pouillart P, Sastre-Garau X . 2000 Eur. J. Cancer 36: 586–591

  • Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P, Frebourg T, Iggo R . 1997 Oncogene 14: 163–169

Download references

Acknowledgements

We thank the technicians of the different laboratories for expert technical assistance, M Dreyfus for revising the manuscript and are grateful to Professors A Janin and Y Beuzard for support and helpful discussions. These investigations were supported by PHRC and ARC.

Author information

Author notes

  1. Elizabeth Turpin and Ivan Bièche: Elizabeth Turpin and Ivan Bièche contributed equally to this study

Authors and Affiliations

  1. Service de Biochimie B and CNRS UPR9051, Hôpital Saint Louis, 1, Avenue Claude Vellefaux, Paris, Cedex 10, F-75475, France

    Elizabeth Turpin, Louis-François Plassa & Hughes de Thé

  2. Laboratoire de Génétique Moléculaire UPRES JE 2195, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, 4 Avenue de l'Observatoire, Paris, F-75006, France

    Ivan Bièche, Martine Olivi & Michel Vidaud

  3. Laboratoire d'Oncogénétique E0017 INSERM, Centre René Huguenin, 35, Rue Dailly, St-Cloud, F-92210, France

    Ivan Bièche, Florence Lerebours & Rosette Lidereau

  4. Service d'Anatomie Pathologique and ERM 0220 INSERM, Hôpital Saint Louis, 1, Avenue Claude Vellefaux, Paris, Cedex 10, F-75475, France

    Philippe Bertheau & Anne de Roquancourt

  5. Service d'Oncologie, Hôpital Saint Louis, 1, Avenue Claude Vellefaux, Paris, Cedex 10, F-75475, France

    Florence Lerebours, Marc Espié & Michel Marty

Authors
  1. Elizabeth Turpin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivan Bièche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philippe Bertheau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Louis-François Plassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Florence Lerebours
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anne de Roquancourt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martine Olivi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marc Espié
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michel Marty
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Rosette Lidereau
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michel Vidaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hughes de Thé
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hughes de Thé.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turpin, E., Bièche, I., Bertheau, P. et al. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 21, 7593–7597 (2002). https://doi.org/10.1038/sj.onc.1205932

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205932

Keywords

This article is cited by

Search

Advanced search

Quick links